title: The role of imiquimod 3.75% cream in the treatment of external genital warts.
abstract: Imiquimod 3.75% cream has recently been approved by both the U.S. Federal Drug Administration and Health Canada for the treatment of external genital warts. Herein, we provide an overview of external genital warts, review the phase 3 clinical trials leading to the approval of imiquimod 3.75% cream, and compare its efficacy and clinical use with imiquimod 5% cream. Moreover, therapeutic options have further expanded with the relatively recent introduction of sinecatechins 15% ointment, an extract of green tea leaves.
authors.affiliation: Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Berman
authors.forename: Joel
authors.initials: J
authors.lastname: Wolf
mesh_terms: D000287:Administration, Topical; D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D002170:Canada; D017326:Clinical Trials, Phase III as Topic; D003218:Condylomata Acuminata / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use*; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use; D013662:Tea / Q000737:chemistry; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000634:Aminoquinolines; D007369:Interferon Inducers; D010936:Plant Extracts; D013662:Tea; D000077271:Imiquimod